BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Drug Development

  How AI Could Ease Tension in Clinical Trials

  In the third episode of our mini series on artificial intelligence, Lori and guests continue their exploratory discussion on AI and the opportunity in patient lives.

  October 10, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Legal

  GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines

  The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer. Analysts say separate concerns remain about its vaccines business.

  October 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Gene therapy

  7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study

  The pediatric patients, with a rare neurodegenerative disease, were treated with bluebird bio’s Skysona to slow the progression of neurologic dysfunction. Six patients developed myelodysplastic syndrome and one patient developed acute myeloid leukemia.

  October 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Astellas Cuts 24 Universal Cells Roles in Seattle, Transfers 12 to Japan

  Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

  October 10, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Bankruptcy

  Gritstone Files for Bankruptcy in Effort to Save Clinical Research

  Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the company hopes will save its clinical research in cancer and infectious disease.

  October 10, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  People

  From Argentina to America: A Physician’s Journey to Pharma and AstraZeneca

  Carlos Doti has moved countries and changed jobs, but one thing hasn’t changed. Making an impact on patient care has always been a priority for the AstraZeneca executive.

  October 10, 2024

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Prostate cancer

  Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo

  The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, potentially covering all patients with metastatic castration-resistant prostate cancer regardless of biomarker status.

  October 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  INCOG BioPharma Accelerates Expansion Plans

  October 10, 2024

   · 

  4 min read
• Press Releases

  Cingulate Announces Adjournment of Special Meeting

  October 10, 2024

   · 

  2 min read
• Press Releases

  Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis (LCA16)

  October 10, 2024

   · 

  4 min read